期刊文献+

CTNP与CHOP方案治疗非霍奇金淋巴瘤的疗效比较 被引量:4

下载PDF
导出
摘要 目的比较CTNP与CHOP方案治疗非霍奇金淋巴瘤(NHL)的疗效及不良反应。方法将129例患者随机分为两组,采用CTNP方案治疗63例,采用CHOP方案治疗66例;每28 d重复疗程,全部患者治疗6~8个周期。结果初发患者以CTNP方案治疗后有效(CR+PR)率为86.66%,复发或难治患者的有效率为72.72%;CHOP方案治疗初发患者的有效率为80.00%,复发或难治患者的有效率为45.16%。两种方案对于初发患者的疗效相似,对复发或难治患者疗效差异有统计学意义(P<0.05)。贫血、白细胞减少、血小板减少、肝、肾功能损害、静脉炎等不良反应发生率差异无统计学意义(P>0.05);但CTNP组心电图异常、脱发、周围神经损害及胃肠道反应发生率低于CHOP组,差异有统计学意义(P<0.05)。结论CTNP方案治疗复发或难治患者的疗效显著,副反应发生率低,可替代CHOP方案治疗NHL。
出处 《苏州大学学报(医学版)》 CAS 北大核心 2008年第3期470-473,共4页 Suzhou University Journal of Medical Science
  • 相关文献

参考文献12

二级参考文献33

  • 1丁永为.序贯短程大剂量联合化疗治疗?60例恶性淋巴瘤[J].中华血液学杂志,1993,14(9):488-489. 被引量:2
  • 2勇威本,高非,孙红,白羽,王淑娴,刘彤.BCOPP/CHOP─B治疗非何杰金淋巴瘤疗效观察[J].北京医学,1995,17(2):65-68. 被引量:2
  • 3万德林.临床肿瘤学[M].北京:科学出版社,1999.269-279.
  • 4江明.药理学[M].北京:人民卫生出版社,1989.92-283.
  • 5Fisher R I, Gaynor E R, Dahlerg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma[J]. N Engl J Med, 1993, 328:1002.
  • 6Gorndon L, Harrington D, Anderson J, et al. Comparison of a second-generation combination chemotherapy regimen (m-BACOD) with a stardard regimen (CHOP) for advanced diffuse nonHodgkin's lymphoma[J]. N Engl J Med, 1992, 327:1342.
  • 7Tone H, Kurebe M, Takeuchi T, et al. Experimental studies on(2"R)4'-0-Tetrahydropyranyladriamycin (THP)[A]. In Kuemmerle HP ed. Advance in experimental and clinical chemotherapy[M]. Landsbeg/Lech: Ecomed, 1988 : 1-9.
  • 8Okuma K, Furuta I, Ota K. Acute cardiotoxicity of antharacyclines-analysis by using Holter EKG[J]. Jpn J Cancer Chemother, 1984, 11(4): 901.
  • 9Dinarello CA, Interleurin-Land is biologieally laled Cytorines[J]. Aavimmunol,1989,44(2):153-155.
  • 10Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 1994, 84: 1361-1392.

共引文献24

同被引文献33

  • 1杜俊凯,王倩.原发性胃恶性淋巴瘤37例临床分析[J].陕西医学杂志,2008,37(11):1539-1540. 被引量:3
  • 2杨敏,陈琦,陈羽.非霍奇金淋巴瘤患者血管内皮生长因子、抗凋亡因子Bcl-2与多药耐药关系的初步探讨[J].陕西医学杂志,2006,35(3):289-291. 被引量:7
  • 3姜文奇.非霍奇金淋巴瘤治疗研究新进展[J].循证医学,2007,7(1):2-6. 被引量:2
  • 4Cheson BD,Horning SJ,Coiffier,et al.Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma.J Clin Oncol,1999,17(4):1244-1253.
  • 5Wenwu Wang,Xuenong Ou Yang,Zhangshu Cheng,et al.Clinical randomized comparative trial of DICE reqimen and CHOP reqimen in treating intermediate and high grade non-Hodgkin's lymphoma.Chinese-German J Clinical Oncology,2008,7(2):107-110.
  • 6Kuruvilla J,Nagy T,Pintilic M,et al.Similar response rates and superior early progression-free survival with gemcitabine,dexamethasone,and cisplatin salvage therapy compared with carmustine,ctoposide,cytarabine,and melphalan salvage therapy prior to autologous stem cell transplant for recurrent or refractory Hodgkin lymphoma.Cancer,2006,106(2):353-360.
  • 7Myung Hee Chang,Seok Jin Kimi,Kihyun Kim,et al.Clinical features and treatment outcomes of adult B-and T-lymphoblastic lymphoma:results of multicentre analysis in Korea.Leukemia & Lymphoma,2009,50(7):1119-1125.
  • 8Michallet AS,Coiffier B.Recent developments in the treatment of aggressive non-Hodgkin lymphoma[J].Blood Rev,2009,23(1):11-23.
  • 9Sonet A,Bosly A.Rituximab and chemotherapy in diffuse large B- cell lymphoma[J].Expert Rev Anticancer Ther,2009,9(6):719-726.
  • 10Tucci A,Ferrari S,Bottelli C,et al.A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy[J].Cancer,2009,115(19):4547-4553.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部